{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-279108","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.610280+00:00","generated_at":"2026-06-22T05:31:12.650227+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Verrica Q3 net income $83K; reiterates VP-102 NDA resubmission in Q1 2023","bullets":["Q3 GAAP net income of $83K ($0.00/sh) vs net loss of $12.8M in Q3 2021; non-GAAP net income $2.9M ($0.07/sh).","License revenue of $8.3M from Torii milestone; cash, equivalents and marketable securities total $39.5M.","Reiterates plan to resubmit NDA for VP-102 (molluscum contagiosum) in Q1 2023.","Phase 2 trial of VP-LTX-315 (basal cell carcinoma) Part 1 expected to conclude in Q1 2023.","R&D and G&A expenses declined vs prior year due to reduced headcount and lower CMC costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-279108","json":"https://secwatch.observer/filing/0001193125-22-279108.json","markdown":"https://secwatch.observer/filing/0001193125-22-279108.md","text":"https://secwatch.observer/filing/0001193125-22-279108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312522279108/0001193125-22-279108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312522279108/d397144d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:31:12.650227+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ebe2a2b221cec5c58dfab98cf1e727e43831d98","claim":"Verrica Pharmaceuticals Inc. reported nine months ended September 30, 2022 results: revenue $9.0 million, net income net loss of $18.6 million, EPS $0.58 per share.","evidence_excerpt":"million, or $0.40 per share, for the same period in 2021. Year-to-Date September 2022 Financial Results • Verrica recognized license revenues related to the Torii Agreement of $9.0 million for the nine months ended September 30, 2022 compared to $12.0 million for the same period in 2021. The current period license revenue was related to an $8.0 million milestone","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312522279108/0001193125-22-279108-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2022"},{"label":"Revenue","value":"$9.0 million"},{"label":"Net income","value":"net loss of $18.6 million"},{"label":"EPS","value":"$0.58 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d19afe47909ec66ac5e6257e6f3cb3ab63122ad1","claim":"Verrica Pharmaceuticals Inc. reported the third quarter ended September 30, 2022 results: revenue $8.3 million, net income $83 thousand, EPS $0.00 per share.","evidence_excerpt":"Part 1 (safety and dose escalation) is expected to conclude in Q1 2023. Financial Results Third Quarter 2022 Financial Results • Verrica recognized license revenues of $8.3 million for the three months ended September 30, 2022 and no license revenue for the same period in 2021 related to the Collaboration and License Agreement (the “Torii Agreement”) with","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312522279108/0001193125-22-279108-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$8.3 million"},{"label":"Net income","value":"$83 thousand"},{"label":"EPS","value":"$0.00 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}